Addressing the silent epidemic of antimicrobial resistance in the African region: a scoping review of evidence gaps and research considerations Authors: Chinwe Iwu-Jaja, Laetitia Gahimbare, Yidnekachew Degefaw Mazengiya, Joseph Okeibunor, Olushayo Oluseun Olu, Anelisa Jaca, Akhona V Victress Mazingisa, Chidozie D Iwu, Ali Ahmed Yahaya, Charles Shey Wiysonge Published: 2026 ABSTRACT AbstractObjectivesThis scoping review mapped antimicrobial resistance (AMR)-related interventions in WHO African region against the five strategic objectives of the WHO Global Action Plan (GAP) on AMR and identified evidence gaps limiting progress.DesignA scoping review using the Arksey and O’Malley framework, enhanced by Levac et al and Joanna Briggs Institute methodology; reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR).Data sourcesPubMed, CINAHL, Web of Science and Scopus searched on 9 December 2025, with grey literature from Google Scholar and Google (first 100 hits).Eligibility criteriaStudies of any design reporting interventions addressing GAP strategic objectives—stewardship, surveillance, infection prevention, education or economic approaches in the WHO African region.Data extraction and synthesisData were charted using a pilot-tested Excel tool by GAP strategic objective and evidence gaps and research considerations were synthesised thematically.ResultsForty-nine studies (2016–2025) were included, with country-specific evidence concentrated in South Africa, Ethiopia, Kenya, Ghana and Nigeria. Most evaluated antimicrobial stewardship or awareness/training interventions in tertiary hospitals, showing improvements in prescribing, knowledge and occasional cost savings but few assessed long-term effects or resistance trends. Surveillance had advanced but remained limited by weak laboratory capacity, diagnostic coverage, data quality and limited use of AMR/antimicrobial use data in practice. Evidence on infection prevention, vaccination and One Health interventions was scarce and no full economic evaluations were identified.ConclusionsAMR research in the African region clusters around antimicrobial stewardship and awareness in tertiary hospitals, leaving infection prevention, vaccination, One Health approaches and economic evaluation substantially underrepresented across the GAP framework. Closing these gaps will require longer-term implementation research, context-specific economic analyses and broader geographical coverage to generate the evidence needed to operationalise the global AMR research agenda in Africa.Keywords: Epidemiology, Public Health, Scoping Review WHAT IS ALREADY KNOWN ON THIS TOPIC Antimicrobial resistance poses a disproportionate burden in Africa, with an estimated 250 000 direct antimicrobial resistance (AMR)-related deaths annually. Antimicrobial resistance poses a disproportionate burden in Africa, with an estimated 250 000 direct antimicrobial resistance (AMR)-related deaths annually. The WHO Global Action Plan on AMR provides a framework for coordinated action across five strategic objectives, though implementation in African settings has been limited. The WHO Global Action Plan on AMR provides a framework for coordinated action across five strategic objectives, though implementation in African settings has been limited. WHAT THIS STUDY ADDS This is the first comprehensive mapping of AMR interventions across the African region against all five Global Action Plan objectives that identified critical evidence gaps and research considerations. This is the first comprehensive mapping of AMR interventions across the African region against all five Global Action Plan objectives that identified critical evidence gaps and research considerations. Research activity is unevenly distributed, with the bulk of studies focusing on antimicrobial stewardship and awareness/training, while infection prevention, One Health approaches and economic evaluations remain significantly under-represented. Research activity is unevenly distributed, with the bulk of studies focusing on antimicrobial stewardship and awareness/training, while infection prevention, One Health approaches and economic evaluations remain significantly under-represented. The evidence base is geographically concentrated, with most studies originating from a small group of countries (such as South Africa, Ethiopia, Nigeria, Kenya and Ghana), resulting in substantial knowledge gaps across other parts of the region. The evidence base is geographically concentrated, with most studies originating from a small group of countries (such as South Africa, Ethiopia, Nigeria, Kenya and Ghana), resulting in substantial knowledge gaps across other parts of the region. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY The findings highlight an urgent need for context-specific implementation research, particularly in underrepresented countries, rural areas and primary care settings. The findings highlight an urgent need for context-specific implementation research, particularly in underrepresented countries, rural areas and primary care settings. Infection and Prevention and Control-focused studies that measure AMR-specific outcomes, along with comprehensive economic evaluations, are critical to strengthen the evidence base. Infection and Prevention and Control-focused studies that measure AMR-specific outcomes, along with comprehensive economic evaluations, are critical to strengthen the evidence base. Strengthening the integration of AMR/AMU surveillance data into clinical practice and policy formulation can support more effective stewardship and decision-making. Strengthening the integration of AMR/AMU surveillance data into clinical practice and policy formulation can support more effective stewardship and decision-making. Building stronger investment cases and embedding One Health approaches across sectors will be essential for sustaining long-term AMR control in Africa. Building stronger investment cases and embedding One Health approaches across sectors will be essential for sustaining long-term AMR control in Africa. Introduction Antimicrobial resistance (AMR) remains one of the major global public health threats, with far-reaching economic implications.1 2 Although AMR is a natural evolutionary process,3,5 the current rate of spread is alarming, driven by selective pressure from the misuse and overuse of antimicrobials, as well as lack of access to appropriate treatment.1 This threatens our ability to treat common infections and undermines the success of critical procedures such as chemotherapy, surgeries and organ transplantation.6 In 2021, AMR contributed to an estimated 4.71 million deaths globally, with 1.14 million directly attributable to resistant infections.7 By 2050, it has been projected that direct AMR deaths would reach 1.91 million and indirect deaths would rise to 8.22 million annually.7 The burden is particularly heavy in the African region, where an estimated 1.05 million deaths were associated with bacterial AMR in 2019, and 250 000 directly caused by AMR.8 This high mortality underscores the urgency for action.8 The economic implications are equally dire. Without robust action, the cost of treating resistant infections is projected to reach $412 billion annually by 2035.9 For low- and middle-income countries (LMICs), including those in Africa, this represents a particularly severe threat to already fragile health systems.9 Compounding this challenge are risk factors prevalent across African countries such as poverty, overcrowding, poor sanitation, contaminated food and water, and weak surveillance systems.10 11 Addressing AMR requires harmonised, cross-sectoral collaboration between health, agriculture, veterinary and environmental sectors, researchers, civil society and communities.12 Recognising this, WHO launched the Global Action Plan (GAP) on AMR in 2015 to provide countries with a structured framework for response. Its five strategic objectives include ‘improving awareness, strengthening the evidence base, reducing infections, optimizing antimicrobial use and building the economic case for sustained investment’.13 However, implementation in Africa has been shown to be limited, with several countries facing persistent challenges in translating national action plans (NAPs) into measurable progress.14 Previous studies have examined the status of implementation of NAPs15 health system interventions in selected countries16 and challenges in tackling AMR across Africa.17 Furthermore, several global and regional frameworks now provide benchmarks for research and implementation. The WHO Global Research Agenda for Antimicrobial Resistance in Human Health (2023) identifies priority research topics to guide evidence generation towards 2030.18 The Quadripartite One Health Priority Research Agenda for Antimicrobial Resistance (2023) highlights cross-sectoral priorities across human, animal and environmental health.19 At regional level, the WHO African region adopted the Regional Strategy for Expediting the Implementation and Monitoring of National Action Plans on AMR, 2023–2030, which outlines targets for governance, surveillance, antimicrobial use and awareness across the 47 Member States.20 21 This global research agenda also calls for priority topics to be translated into tangible, fundable and context-appropriate research proposals, especially for resource-limited settings.19 However, there is limited synthesis of how existing evidence aligns with these priorities in the African region. This scoping review addresses this gap by mapping intervention-focused evidence from the African region against the GAP objectives and identifying region-specific research gaps in relation to these priorities. Mapping regional evidence gaps against global AMR research priorities is essential to ensure that African research investments and policy actions are aligned with both global commitments and regional needs. Therefore, this scoping review aims to systematically map intervention-focused AMR evidence in the WHO African region against the GAP objectives and existing research priorities and to identify gaps where evidence is lacking or insufficient to inform policy and implementation. Methods We conducted this scoping review using five key steps, following the Arksey and O’Malley’s framework which was enhanced by Levac et al.: (1) defining the research question, (2) identifying relevant studies, (3) selecting studies, (4) charting the data and (5) collating, summarising and reporting the results.22,25 The final write-up was guided by the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR).26 A protocol was previously developed for this review.27 Identification of relevant studies/search strategy We searched multiple electronic databases including PubMed, CINAHL, Web of Science and Scopus using a combination of search terms related to ‘antimicrobial resistance’, ‘Africa’. Additional grey literature was sourced from Google Scholar and standard Google search engine results (first 100 hits). A detailed search strategy is provided in online supplemental tables 1–4, respectively. The literature search was conducted on 9 December 2025. Inclusion and exclusion criteria We applied the Population Concept and Context (PCC) framework from the JBI to guide our eligibility criteria.24 25 The Population included individuals, health facilities or systems involved in AMR-related work in Africa. The Concept focused on interventions aimed at addressing AMR (including stewardship, surveillance, infection prevention, education and economic approaches). The Context was limited to the WHO African region, although we also included studies with a global or LMIC-wide scope if Africa was part of the focus. We included studies of any design that reported on interventions related to one or more GAP strategic objectives. We excluded opinion pieces or articles that did not provide evidence-based findings or that had no reference to Africa. Study selection All search results were imported into Rayyan software for screening. Two reviewers (CIJ and AM) independently screened the titles and abstracts for relevance. Full-text screening was then conducted by the same reviewers using the inclusion and exclusion criteria. All disagreements were resolved through discussion. Charting the data A standardised and internally pilot-tested Excel-based data extraction tool was used to chart relevant details from the included studies. Information captured included study ID, year of publication, country or region, intervention type, targeted population, study design, AMR GAP strategic objective addressed, outcome measures, key findings and reported research or implementation gaps. Collating, summarising and reporting the results We categorised extracted data according to the five GAP objectives and synthesised findings narratively. Outcome measures were mapped against GAP indicators and evidence gaps were identified directly from the included studies through an iterative data-charting process. For each study, we extracted statements describing limitations, unmet needs, methodological weaknesses or implementation challenges related to AMR interventions and inductively synthesised them into broader categories aligned with the GAP objectives. To ensure policy relevance, these gaps were compared with AMR priorities outlined in WHO/AFRO documents without introducing gaps not supported by the included evidence. Research considerations were developed by translating each gap into a researchable question, emphasising areas requiring further primary or implementation research, methodological strengthening or contextual inquiry. Operational recommendations were excluded unless they reflected an explicit research need. The final set of gaps and research considerations therefore reflects the empirical limitations of the available studies while remaining consistent with established AMR frameworks. Results Results from literature search We retrieved a total of 11 300 publications from the literature search and three additional studies from grey literature, from which 5022 duplicates were removed. We then screened the titles and abstracts of the remaining 6281 publications for potential eligibility. Of these, 89 articles were selected for full-text screening. Ultimately, 49 publications met our eligibility criteria and were included in this review. Figure 1 outlines these steps. To complement the findings from the included studies, we also drew on data from the WHO Tracking AMR country self-assessment survey (TrACSS) reporting system to provide additional context on AMR surveillance coverage and system readiness in the Region.28 These data were not part of the formal study inclusion but were used to support interpretation of surveillance-related gaps. PRISMA flow diagram showing process of study selection. From Moher et al.81 For more information, visit www.prisma-statement.org. AMR, antimicrobial resistance; CINAHL, Cumulative Index of Nursing and Allied Health Literature; PRISMA, Preferred Reporting Items for Systematic reviews and Meta-Analyses. Overview of included studies and geographical distribution This scoping review included a total of 49 studies published between 2016 and 202529,77 (online supplemental table 5). Nine studies were Africa-focused or regional in scope,30,3234 37 56 60 61 67 72 while the majority of country-specific studies came from South Africa (n=9).33 35 38 46 54 64 65 70 73 75 This is followed by four studies each from Ethiopia42 45 62 66 and Nigeria,55 64 69 74 three from Uganda36 43 57 and two each from Egypt,68 76 Ghana,39 59 Kenya,52 77 Malawi53 72 and Tanzania.44 63 One study each was identified from Benin,48 Mali,58 Mozambique,41 Rwanda,29 Sierra Leone,40 Tunisia50 and Zambia.71 Three additional studies were global in scope but included African data.47 49 51 Study designs and focus Eight studies utilised before-and-after (pre–post) designs to evaluate the effect of antimicrobial stewardship (AMS) interventions or surveillance improvements in clinical or laboratory settings. One study assessed the impact of a hospital-wide antimicrobial stewardship programme (ASP) on antibiotic consumption, costs and patient outcomes over 4 years in a South African tertiary hospital. The intervention included online education, a dedicated prescription chart and structured ward rounds.73 Another study implemented an antibiotic prescription chart in a South African paediatric medical ward and reviewed its influence on antibiotic use.65 A quasi-experimental study conducted in an Egyptian emergency intensive care unit evaluated the effects of comprehensive AMS actions such as antibiogram development, guideline implementation and staff training on antibiotic use in device-associated infections.76 A similar quality improvement intervention was evaluated in surgical wards across Ethiopian hospitals to optimise prophylactic antibiotic use.62 In Tanzania, one pilot before–after study assessed the effects of revising a routine surveillance system for multidrug-resistant tuberculosis. Outcome measures included the number of tested specimens, feedback timelines and the number of detected MDR-TB cases.44 A study in Sierra Leone used a pre–post design to improve antimicrobial prescribing practices among paramedical staff in outpatient departments through AMS interventions.40 Two studies employed training-based interventions. One evaluated the impact of a training programme on laboratory scientists’ capacity to conduct genomic surveillance of AMR in Kenya.77 The other used a train-the-trainer model to strengthen laboratory professionals’ diagnostic and antimicrobial susceptibility testing skills across clinical and veterinary laboratories in Benin.48 Additionally, an online massive open online course on AMS was also evaluated using a pre–post design to assess global learning impact including African countries.47 A feasibility study assessed the establishment of microbiology diagnostic capacity for AMR testing in rural district hospitals in Rwanda including infrastructure, training and cost estimation.29 Three implementation studies evaluated AMS interventions. One assessed audit and feedback effects on prescribing in a Nigerian paediatric ward.69 Another examined a pharmacist-led ASP across 47 South African hospitals.70 A multicentre study implemented a neonatal ASP across South African hospitals.75 We identified one randomised crossover trial which evaluated a smartphone-based clinical decision support tool using a diarrhoeal aetiology prediction algorithm to guide antibiotic use for acute diarrhoea in children in Mali.58 Thirteen studies employed cross-sectional designs to assess the status, knowledge, attitudes, practices (KAPs) and implementation of AMS, AMR surveillance and public awareness across various settings. These include facility-based AMR and surveillance assessments within healthcare facilities including evaluations of AMS activities in Tanzanian hospitals 1 year after the NAP launch and in tertiary hospitals in Nigeria and Tunisia.50 55 63 A baseline assessment conducted in public hospitals in Malawi evaluated the implementation of AMS core elements, highlighting wide variation in governance structures, limited routine audit and feedback and weak integration of antimicrobial use data into AMS activities.72 One study in South Africa reviewed the impact of stewardship ward rounds using patient records in surgical wards.35 Similarly, AMS capacity and Infection and Prevention and Control (IPC) practices were assessed in three hospitals in Ghana59 and antibiotic prescribing patterns were described among paediatric patients at a Nigerian tertiary hospital.64 Studies targeting healthcare workers and the general public explored knowledge and attitudes regarding antimicrobial use. These included assessments among paramedics in Ethiopia,66 informal transport workers in South Africa46 and dairy farmers in Addis Ababa45 and residents in Ghana.39 An Africa-wide survey of nurses also evaluated their role in antimicrobial use and stewardship training.56 One cross-sectional study from Uganda characterised resistance patterns of Neisseria gonorrhoeae using data from a newly implemented surveillance programme.36 We found only one qualitative study which explored community knowledge and practices on antibiotic use and awareness of antibiotic resistance in rural Mozambique to inform communication strategies.41 Five studies employed descriptive or situational designs to document training, stewardship and surveillance initiatives. One study described the development and rollout of a national AMR training curriculum for healthcare workers in Kenya, reaching over 500 staff across 19 counties and expanding through an e-learning platform.52 In South Africa, a study explored how regular AMS ward rounds fostered a culture of AMS in a rural hospital,38 another described how Ethiopia established a sentinel AMR surveillance network42 and a third study documented South Africa’s governance and multisectoral actions on colistin use.54 A prospective surveillance study established a standardised gonococcal AMR surveillance programme in Uganda to monitor antimicrobial susceptibility patterns of N. gonorrhoeae,43 while a retrospective observational study analysed AMR surveillance data for N. gonorrhoeae to inform treatment guidelines and priorities.51 Two document reviews assessed antimicrobial interventions. One examined national AMR action plans across Africa, highlighting vaccine inclusion in reducing infection burden.30 Another reviewed adherence to antibiotic stewardship in hospitalised children in South Africa, showing improved compliance with national guidelines over time.33 While a programme report described Uganda’s implementation of a One Health approach to strengthen IPC and AMS capacity including training over 5000 health workers and addressing 32 WHO benchmark actions across AMR coordination, IPC and AMS.57 Three systematic reviews and one narrative review synthesised evidence on AMR surveillance, AMS and awareness. One review summarised AMR rates and surveillance efforts across sub-Saharan Africa.32 Systematic reviews assessed pharmacist-led AMS programmes,67 the extent and impact of AMS implementation34 and education and awareness interventions across the African region.37 A global review described surveillance systems for N. gonorrhoeae including contributions from African countries.49 Evidence mapped by GAP strategic objectives Strategic objective 1: improve awareness and understanding of antimicrobial resistance through effective communication, education and training Studies under GAP objective 1 showed improved AMR awareness through educational and AMS interventions. Structured training52 online courses47 and leadership programmes31 enhanced knowledge among health workers. Additionally, AMS rounds and pharmacist-led interventions reduced inappropriate prescribing.35 70 Campaigns68 improved antibiotic use. However, surveys among community members39 41 45 46 revealed persistent misconceptions despite awareness. Gaps remain in sustaining behaviour change, contextualising messaging and institutionalising AMS training. Regional TrACSS findings provide further context on awareness and education efforts across the African region.28 In 2023, 32.6% (15 of 46) of responding countries reported government-supported AMR awareness campaigns implemented nationwide (levels D and E) while another 32.6% (15 countries) reported limited or small-scale campaigns (level C). The human health sector was the most engaged in awareness activities (78.2% of countries) followed by food safety (60.8%). Training for health professionals showed similar variability. More than half (54.3%, 25 of 46) of countries reported providing some level of AMR training for human health workers (levels C–E) with level C offering some pre- and in-service training reported by 52.1% (24 countries). However, only one country (2.1%) reported systematic integration of AMR into national training curricula (level E). Trend data from TrACSS show limited improvement in this indicator over recent years. Strategic objective 2: strengthen knowledge and the evidence base through surveillance and research Our review revealed notable progress in AMR surveillance including for gonorrhoea and tuberculosis. Sentinel networks and national systems improved data availability,29 42 43 while genomic surveillance showed feasibility in public laboratories.77 High resistance to commonly used antibiotics was documented.36 51 Despite this, data use remains limited, many countries still lack functional national AMR surveillance systems and evidence on how surveillance informs antibiotic use or resistance trends is limited with inconsistent record-keeping.63 Studies called for standardised methods, broader coverage and capacity investments to strengthen regional AMR evidence base.32 49 TrACSS findings mirror these observations. In 2023, 50% (23 of 46) of responding countries reported collating AMR data nationally (levels C–E) and among these, 86.9% (20 countries) had a standardised national surveillance system with a coordinating centre and reference laboratory. However, only 36.9% (17 countries) reported using surveillance data to inform operational decisions. Clinical bacteriology capacity varied: 59% (27 countries) had at least one reference laboratory performing susceptibility testing for all 11 priority pathogens and 56.5% (26 countries) used standardised AST guidelines.28 Monitoring of antimicrobial consumption and use remained limited. Only 30.4% (14 countries) reported having a national AMU monitoring system and 10.8% (5 countries) reached the highest level of regular national reporting. More than half of countries—56.5% (26 countries) reported no national system for AMU monitoring (level A). TrACSS data also showed that none of the countries had fully linked AMR surveillance to AMU/AMC data, a requirement for the highest level of surveillance maturity.28 Strategic objective 3: reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures Evidence mapped under GAP objective 3 was limited. Two studies reported IPC components as part of broader AMR strategies, including hand hygiene promotion and facility-level IPC strengthening.57 59 Only one study explicitly examined vaccination as an AMR-related prevention strategy and found minimal integration of vaccines into national AMR plans.30 TrACSS findings reflect similar challenges. In 2023, 13% (6 of 46) of responding countries reported nationwide implementation of IPC programmes aligned with WHO IPC core components (levels D and E), and 6.5% (3 countries) reached the highest level, with functioning national and facility-level IPC systems regularly monitored and updated. A larger proportion, 36.9% (17 countries), reported having national IPC programmes, operational plans and guidelines in place, with selected facilities implementing IPC standards and receiving monitoring feedback (level C). However, the most frequent response was level B, reported by 43.4% (20 countries), where national programmes and standards exist but are not fully implemented. A small number of countries (6.5%, n=3) reported having no national IPC programme or operational plan (level A). Trend data show limited improvement in nationwide IPC implementation between 2021 and 2023.28 Strategic objective 4: optimise the use of antimicrobial medicines in human and animal health The majority of included studies evaluated AMS interventions aimed at optimising the use of antibiotics across a variety of clinical and programmatic settings. These interventions ranged from pharmacist-led initiatives,67 74 prescription audits and feedback,69 optimisation of surgical prophylaxis,62 implementation of prescription tools65 and digital or guideline-based decision-support systems.58 61 Most studies reported improved compliance with treatment guidelines, reductions in inappropriate prescribing and antibiotic consumption, and, in some cases, cost savings.53 73 However, few studies evaluated the direct impact on resistance patterns or clinical outcomes such as mortality. Important gaps also remain in the use of rigorous study designs, long-term follow-up and the integration of AMS across both human and animal health sectors.34 40 50 54 55 58 59 61 Cross-sectional assessments further highlighted variability in AMS implementation across health systems. A baseline assessment conducted in public hospitals in Malawi identified wide variation in the implementation of AMS core elements, with leadership and governance structures more commonly established than routine audit and feedback, antimicrobial use monitoring or integration of laboratory data into stewardship activities.72 TrACSS findings provide additional context for AMS implementation in the Region. In 2023, 41% (19 of 46) of responding countries reported having national guidelines for appropriate antimicrobial use and implementing AMS programmes in some health facilities (levels C–E). Only three countries reported nationwide implementation of these guidelines in most facilities (levels D and E), and one country reached level E, where guideline implementation is routinely monitored and feedback provided. Regulations on prescription and sale of antimicrobials were reported by 80% (37 countries). Adoption of the Access, Watch, Reserve (AWaRe) classification into national essential medicines lists was documented in 56.5% (26 countries), although only 8.6% (4 countries) had integrated AWaRe into stewardship strategies and monitored consumption using the classification. Monitoring systems for antimicrobial consumption and use were less established; 30.4% (14 countries) reported having a national AMU monitoring system, and 10.8% (5 countries) reported regular national-level monitoring and reporting. A substantial proportion, 43.3% (20 countries)—reported no or weak national policies for appropriate antimicrobial use (level A), and many countries had knowledge of AWaRe, but had not adopted or operationalised it.28 GAP objective 5: develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions This objective represented the most significant gap in the evidence base, with no studies specifically focused on economic evaluations or investment cases for AMR interventions. While some studies mentioned cost savings or conducted limited cost analyses following AMS interventions,53 62 73 74 76 comprehensive economic evaluations were notably absent. There was also a lack of studies focusing on the development of new diagnostics, antimicrobials or other innovations, highlighting a gap in research and development efforts within the region. Objective 5 is not assessed within the TrACSS questionnaire, as its focus on global-level investment and development of new tools falls outside the survey’s mandate. However, related indicators on sustainable financing for AMR action plans provide relevant context. In 2023, 32.6% (15 countries) reported that their national AMR action plan had been costed and budgeted with an operational plan and monitoring mechanism (level D).28 No country reached level E, which requires financial provision for AMR action plan implementation to be formally included in national government budgets. A detailed summary of the characteristics of all included studies, including the evidence gaps they reported, is provided in online supplemental table 5. A consolidated synthesis of the knowledge gaps and research priorities mapped across the GAP strategic objectives is presented in table 1. Table 1Evidence gaps and research considerations on AMR interventions in the African regionEvidence gapsResearch considerations GAP objective 1: improve awareness and understanding of AMR Limited understanding of behavioural and contextual drivers behind inappropriate antibiotic useConduct qualitative and mixed-methods studies to identify behavioural, cultural, economic and health-system barriers to appropriate antibiotic useLimited evidence on long-term impact of AMR training on actual practiceDesign longitudinal studies evaluating how training influences sustained behaviour change and clinical practicesLimited coverage of AMR training in underserved regions and among key cadres (laboratory staff, nurses)Assess training needs, coverage gaps and evaluate models that improve equitable access to AMR/AMS trainingLimited evidence on optimal educational and behaviour-change strategiesEvaluate which educational methods (interactive, digital, peer-learning, community-based) are most effective in reducing misusePoor tracking systems for monitoring postlearning behaviour changeDevelop and test methods to track learners’ real-world behaviour following AMR/AMS trainingLanguage and terminology barriers in AMR communicationStudy the development, acceptability and effectiveness of local-language AMR communication toolsUnder-recognition of nurses and pharmacists in antimicrobial stewardshipConduct research on role optimisation, task-shifting and workforce integration in AMS teams GAP objective 2: strengthen knowledge and the evidence base through surveillance and research Lab infrastructure weaknesses (power, connectivity, equipment) hinder consistent AMR surveillanceExamine how infrastructure constraints affect surveillance data quality and test solutions suitable for resource-limited settingsInconsistent record-keeping and limited use of available digital systems (WHONET, GLASS, LIS)Study barriers to adoption, data-quality issues and strategies to improve completeness and harmonisation of AMR dataLack of standardised methodologies for AMR surveillanceDevelop and validate standardised protocols adapted to African contextsLimited surveillance coverage in some geographies and facility tiersIdentify surveillance blind spots and evaluate models for expanding sentinel and national coverageLimited evidence on how surveillance data influences prescribing behaviour or reduces resistanceEvaluate how clinicians interpret and use surveillance reports, and measure impact on prescribing and outcomesLimited pathogen-specific and genomic surveillance researchExpand research on priority pathogens (eg, N. gonorrhoeae, K. pneumoniae) and test feasible genomic surveillance modelsLimited outcome-linked surveillance researchIntegrate clinical outcomes (mortality, length of stay) into AMR surveillance studies GAP objective 3: reduce infection incidence through IPC, hygiene, WASH and vaccination Limited integration of vaccination as an AMR-reduction strategy in researchConduct studies examining how vaccines reduce antibiotic use and resistance in African settingsVery few studies evaluate IPC as a primary AMR interventionDesign studies with IPC interventions that measure AMR-related outcomes (antibiotic consumption, resistance rates, HAI reduction)Limited understanding of long-term sustainability of IPC capacity-buildingConduct research on the durability of IPC training and capacity-building once external support endsLack of research on interactions between IPC and stewardship programmesEvaluate combined IPC–AMS models to identify synergistic effectsLimited understanding of contextual barriers to IPC practicesConduct qualitative studies on facility-level, cultural, behavioural and resource-related constraints affecting IPC fidelity GAP objective 4: optimise the use of antimicrobial medicines Limited studies linking antimicrobial stewardship interventions to AMR outcomes (resistance, mortality)Conduct rigorously designed studies that statistically assess the impact of AMS interventions on resistance trends and clinical outcomesShort follow-up periods limit understanding of long-term ASP impactDesign longitudinal studies to evaluate the sustainability of AMS effects and long-term resistance trendsLimited evidence across diverse facility types (primary care, rural hospitals)Conduct comparative studies of ASP effectiveness across different health-system levelsPoor sustainability of ASP gains after external support endsStudy factors influencing sustainability (staff turnover, leadership, supply chains) using implementation scienceLimited understanding of prescriber behaviour and barriers to adherenceConduct behavioural and mixed-methods research on decision-making, risk perceptions and motivations behind antibiotic choicesInadequate documentation of prescribing practicesDevelop and evaluate feasible documentation tools and digital prescribing solutions suitable for low-resource settingsContinued preference for broad-spectrum antibiotics despite guidelinesStudy the drivers of persistent Watch/Reserve antibiotic use and test targeted AMS interventionsLimited inclusion of multidisciplinary teams in AMS researchEvaluate the impact of inclusive AMS models (nurses, pharmacists, IPC professionals, CHWs) on prescribing practices GAP objective 5: develop the economic case for sustainable investment Limited understanding of the economic burden of AMR in African countriesConduct national AMR cost-of-illness studies across different sectorsLack of full economic evaluations of AMR interventionsConduct cost-effectiveness, cost–benefit and budget-impact analyses of antimicrobial stewardship, IPC, vaccination and surveillance interventionsNo Africa-specific investment cases for AMRDevelop investment cases tailored to different African contextsLimited evidence on financing mechanisms for AMR activitiesStudy feasible financing models (public, private, donor, pooled and insurance) for AMR interventionsNo research linking AMR financing gaps with health-system and economic impactsEvaluate how underfunding affects surveillance, stewardship, IPC performance and economic outcomesAMR, antimicrobial resistance; AMS, antimicrobial stewardship; ASP, antimicrobial stewardship programme; GAP, Global Action Plan; GLASS, Global Antimicrobial Resistance and Use Surveillance System; IPC, Infection and Prevention and Control; LIS, Laboratory Information System; WASH, Water, Sanitation and Hygiene; WHONET, WHO microbiology laboratory database software. Evidence gaps and research considerations on AMR interventions in the African region AMR, antimicrobial resistance; AMS, antimicrobial stewardship; ASP, antimicrobial stewardship programme; GAP, Global Action Plan; GLASS, Global Antimicrobial Resistance and Use Surveillance System; IPC, Infection and Prevention and Control; LIS, Laboratory Information System; WASH, Water, Sanitation and Hygiene; WHONET, WHO microbiology laboratory database software. Discussion This scoping review highlights the range of interventions implemented to address AMR across the WHO African region and identifies important evidence gaps that limit progress towards the GAP objectives. Across the included studies, meaningful progress was documented in awareness interventions, AMS, improvements in laboratory capacity, surveillance strengthening and IPC initiatives. These findings demonstrate growing recognition of AMR as a regional priority. However, the evidence base remains uneven, and critical research gaps persist particularly in behavioural studies, long-term evaluation of interventions, surveillance integration and economic analysis—areas where targeted research would directly strengthen and sustain ongoing progress towards the GAP objectives. Most research under GAP objective 1 investigated KAPs and behaviours pertaining to AMR, which highlighted common misconceptions and improper use of antibiotics in spite of reported awareness.78 Although programmes like organised training47 52 and community campaigns68 showed potential, very few research looked at long-term behavioural results, particularly at the community level.46 AMR messaging needs to change from broad awareness to behaviour-informed approach integrated into school curriculum, professional development and community involvement if it is to have influence. Institutionalising AMR education calls for a multisectoral strategy including civil society, media and legislators. It should also use culturally relevant communication techniques to promote significant practice changes across the One Health spectrum. While notable progress has been made in establishing sentinel networks and national surveillance systems,29 42 43 surveillance remains uneven across the African region. Additionally, integration of surveillance data into clinical decision-making is weak, and consistent record-keeping remains a challenge.63 These gaps reflect broader health system limitations. Therefore, regional investment in laboratory infrastructure, digital data platforms and workforce capacity is critical to improve the utility and reliability of AMR surveillance.32 49 Equally important is developing mechanisms that effectively link surveillance findings to prescribing practices and policy decisions, potentially through integrated digital systems that facilitate real-time data analysis and dissemination. Implementation research on how surveillance data influences clinical practice could address the evidence gap on surveillance impact. Studies related to reducing the incidence of infection through effective sanitation, hygiene and infection, as it relates to AMR, were considerably under-represented, possibly reflecting the limited integration of IPC and AMR programmes. While some studies reported IPC activities as part of broader AMS or surveillance efforts57 59 more are needed, particularly those assessing the direct impact of IPC on AMR outcomes in resource-limited settings. NAPs should also strengthen interconnections between IPC committees and AMS teams to foster collaboration rather than parallel efforts. Additionally, although many NAPs acknowledge the importance of vaccines, they often lack clear guidance on how vaccines can be strategically promoted and utilised as a tool for AMR mitigation. Greater emphasis should be placed on incorporating specific, actionable strategies for vaccines/immunisation within AMR frameworks. Our review shows a considerable increase in AMS initiatives all over Africa, with proven success in reducing inappropriate antibiotic use. Implementation, on the other hand, stays geographically focused on few countries, such as South Africa, with little data from most African countries.34 Context-specific challenges, including diagnostics challenges, health system limitations, gaps in implementing the core elements of judicious use of antimicrobials and regulatory inadequacies78,80 demand localised strategies to AMS adoption. Moreover, One Health integration in ASPs is lacking, despite the importance of addressing antimicrobial use across sectors.54 Future initiatives should give top priority to well-designed implementation research on these contextual elements. They should also reach beyond tertiary care to include community and animal health sectors, perhaps through targeted peer-learning networks and capacity building in under-represented areas. The absence of comprehensive economic studies represents perhaps the most critical evidence gap identified, potentially undermining advocacy for sustained AMR funding. While several studies reported cost savings from AMS interventions,53 62 73 74 76 these evaluations were limited in scope and methodology in our review. Developing robust economic evidence specifically relevant to African contexts is essential for policy advocacy. This should include assessment of AMR’s economic burden at country level, comprehensive cost-effectiveness analyses of various interventions and development of investment cases that demonstrate returns across health, agricultural and economic sectors. Given resource constraints, identifying high-impact interventions that deliver optimal returns would be particularly valuable for decision-makers. Additionally, research on sustainable financing mechanisms for AMR activities could address the challenge of maintaining programmes beyond initial donor support. As countries increasingly compete for limited health resources amidst multiple health priorities and changing geopolitics, economic arguments will be crucial for securing the political commitment and financial investment needed for effective AMR control. Collaboration between health economists and AMR experts should be prioritised to address this critical evidence gap. Although these gaps reflect long-standing system challenges in the Region, many of them are consistent with global AMR research priorities. The WHO Global Research Agenda for AMR in Human Health and the Quadripartite One Health Priority Research Agenda18 19 both emphasise areas where African research remains limited, including the long-term effectiveness of behavioural interventions, integration of surveillance with AMS and policy decisions, evaluation of IPC strategies in low-resource settings and the need for economic evidence to guide sustainable investment. At the same time, our review highlights region-specific needs that are less visible in the global frameworks, such as the limited evaluation of vaccines as tools for reducing antibiotic use, the scarcity of implementation research linking surveillance results to prescribing practice and the persistent absence of Africa-specific investment cases. Taken together, these findings illustrate both alignment with global priorities, underscoring the need for research that advances the GAP while responding to the unique realities of health systems in the WHO African region. We acknowledge some limitations in our review. First, our findings are mostly from published studies and therefore evidence from unpublished results including programmatic reports may not have been captured. Also, although newer studies may have been published since our last literature search was conducted, we do not envisage any significant change in the pattern of the current findings, especially with the knowledge gaps, which is the key focus of this paper. It would be, as a matter of urgency, for researchers and implementers to begin addressing these persistent gaps through well-designed implementation studies, with a particular focus on context-specific solutions and underserved areas across the African region. Conclusion This scoping review identified important and uneven research gaps in the AMR evidence base across the WHO African region. While AMS and awareness interventions in tertiary care settings have generated encouraging findings, evidence remains thin across all five GAP objectives particularly for IPC, One Health integration, vaccination as an AMR-mitigation tool and economic evaluation. Research output is also geographically concentrated in a small number of countries, leaving much of the Region under-represented and limiting the transferability of current evidence. Closing these gaps will require a deliberate shift towards context-specific implementation research, longer follow-up to capture sustained effects on prescribing and resistance, stronger links between surveillance data and clinical or policy action, integrated IPC–stewardship models and robust economic analyses to underpin investment cases. Coordinated regional effort engaging researchers, national AMR programmes, funders and One Health stakeholders will be essential to translate these priorities into a fundable, context-appropriate research agenda. By clarifying where African research output aligns with global priorities and where the most consequential deficits lie, this review offers region-specific insights to operationalise the WHO Global Research Agenda for AMR and the Quadripartite One Health Priority Research Agenda within the realities of the African region. Supplementary material Footnotes Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research. Data availability statement All data relevant to the study are included in the article. References Associated Data Supplementary Materials Data Availability Statement All data relevant to the study are included in the article.